Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Malignant Melanoma: Update Bulletin [Jan 2016]

Product Code:
Publication Date:
January 2016

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Key Questions Answered in this Update Bulletin:

  • Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?
  • To what extent will Keytruda be used as a first-line therapy for advanced melanoma?
  • Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting? 
  • What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?
  • How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?
  • How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved